STOCK TITAN

Quest Diagnostics Declares Quarterly Cash Dividend

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
dividends

SECAUCUS, N.J., Aug. 16, 2021 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.62 per share, payable on October 20, 2021 to shareholders of record of Quest Diagnostics common stock on October 5, 2021.

About Quest Diagnostics

Quest Diagnostics empowers people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. Quest Diagnostics annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our nearly 50,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives. www.QuestDiagnostics.com.

 

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/quest-diagnostics-declares-quarterly-cash-dividend-301356270.html

SOURCE Quest Diagnostics

Quest Diagnostics, Inc.

NYSE:DGX

DGX Rankings

DGX Latest News

DGX Stock Data

Medical Laboratories
Health Care and Social Assistance
Link
Health Services, Services to the Health Industry, Manufacturing, Dental Laboratories
US
Secaucus

About DGX

quest diagnostics (nyse: dgx) empowers people to take action to improve health outcomes. derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. quest annually serves one in three adult americans and half the physicians and hospitals in the united states, and our 45,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives. the company offers physicians the broadest test menu (3,000+ tests), is a pioneer in developing innovative new tests, is the leader in cancer diagnostics, provides anatomic pathology (ap) services, & interpretive consultation through its medical & scientific staff of about 900 m.d.s & ph.d.s. the company reported 2014 revenues of $7.4 billion. quest diagnostics offers the most extensive clinical testing network in the u.s., with laborator